clinical-trials

IntroductionPancreatic cancer remains a leading cause of death with poor prognosis. Current standard chemotherapies offer limited survival benefits, and no standard treatment exists for patients failing two lines of therapy. Preclinical evidence suggests that targeting MNK and VEGFR pathways can remodel the immunosuppressive tumor microenvironment and enhance immunotherapy efficacy. This study ev…

Once-daily oral elecoglipron produced dose-dependent weight loss in adults with obesity or overweight without diabetes, with mean reductions reaching 10.5% at 26 weeks and 11.8% at 36 weeks in the highest-dose weekly-titration group. The phase 2 trial found no evidence of a weight-loss plateau by 36 weeks, while gastrointestinal adverse events were common but generally manageable.

A Phase 1-2 rare rheumatology program achieved all startup milestones ahead of schedule, enrolled eight healthy volunteer cohorts back-to-back on time, and navigated a fundamentally different enrollment landscape when transitioning to patients. The team managed this while adapting to frequent strategy changes and maintaining close sponsor governance across multiple geographies.

A landmark clinical trial published in the prestigious New England Journal of Medicine found that tranexamic acid reduced transfusions across major surgeries without increasing the risk of dangerous blood clots.

BackgroundAnthracyclines are key for acute myeloid leukemia (AML) but carry serious side effects. This study identifies their side effects across drugs and patient populations using the FDA Adverse Event Reporting System (FAERS).Materials and methodsWe analyzed 1,079 AML cases and 3,622 adverse events (AEs) from FAERS (2004–2024). Disproportionality analyses (PRR, ROR, BCPNN, MGPS) detected AE si…

Aim of the StudyTo observe the efficacy and safety of CQE in rapidly alleviating inflammatory activity in UC.Materials and MethodsCQE extracts were analyzed by UHPLC–Q Exactive Orbitrap–HRMS. This study used a self-controlled design before and after treatment. A total of 114 UC patients were included and treated with traditional rectal enema administration of CQE. Among them, 107 patients complet…

AimsInfliximab (IFX) is widely used for treating Crohn’s disease (CD), but a significant proportion of patients experience primary non-response or loss of response. Early prediction of IFX efficacy is crucial to avoid ineffective treatment, adverse effects, and financial burden. The aim of this study was to develop a stacking model using routine clinical data to predict IFX clinical response.Meth…

IntroductionPharmacogenomics (PGx) is an emerging medicines optimization tool that may support efficacy and safety relating to antipsychotic prescribing. Despite growing drug-gene evidence linked to antipsychotic response, how PGx could be implemented within Early Intervention in Psychosis (EIP) services, including the views of staff, service users, and carers remains underexplored.MethodsSemi-st…

The University of Chicago Medicine Comprehensive Cancer Center (UCCCC) will remain one of the nation's leading sites for cancer clinical research, thanks to a new, six-year, $5 million grant from the National Cancer Institute (NCI).

Scientific Reports, Published online: 09 June 2026; doi:10.1038/s41598-026-56099-z Correction: Effects of DRG pulsed radiofrequency parameters on the clinical outcome for battered sensory never syndrome: a prospective, triple-blind, randomized controlled trial

In a clinical trial, an experimental antibody reduced lean-mass loss in people on a GLP-1 drug. Whether that improves health is unclear.

Nature Medicine, Published online: 05 June 2026; doi:10.1038/s41591-026-04476-6 As presented at the American Diabetes Association Meeting: this randomized phase 2b trial in 230 adults with overweight or obesity shows that aleniglipron, an oral small-molecule GLP1-RA, led to up to 11.3% body-weight loss compared with placebo after 36 weeks of treatment.

IntroductionTo evaluate the efficacy of a novel eye drop formulation containing hyaluronic acid (0.2%) and butyroyl-glutathione (GSHC4, 0.4%) in glaucoma-associated ocular surface disease (G-OSD), and to explore putative mechanisms of action through in vitro assays of corneal epithelial wound healing and cytokine modulation under basal, inflammatory, and oxidative stress conditions.MethodsIn this…

A promising new pancreatic cancer drug that nearly doubled survival times in a recent clinical trial is drawing attention not only for its potential impact on patients, but also for the university research that helped make it possible. In recent clinical trials by oncology company Revolution Medicines, patients who received daraxonrasib live an average of 13.

Designing Smarter Autoimmune Trials for Heterogeneity and Signal Detection Autoimmune diseases represent one of the most complex and heterogeneous areas for drug development, affecting hundreds of millions of patients worldwide. These conditions span a wide spectrum of clinical phenotypes, immunological drivers, and progression patterns. As therapeutic innovation accelerates—particularly with bio…

A large phase 3 clinical trial has revealed promising results for a once-nightly pill designed to treat obstructive sleep apnea by targeting the biological mechanisms that cause airway collapse during sleep. A once-nightly pill significantly improved obstructive sleep apnea (OSA) symptoms in a large phase 3 clinical trial presented at the 2026 ATS International Conference. [...]

Nature Medicine, Published online: 02 June 2026; doi:10.1038/s41591-026-04442-2 A randomized, single-blind, parallel-group, phase 1b clinical trial compared fecal microbiota transplant or a 15-strain live biotherapeutic product (MTC01) derived from the same donor and found similar efficacy and engraftment between treatments.

The University of Chicago has been awarded $66 million in renewal funding from the National Cancer Institute (NCI) to support the NRG Oncology Statistics and Data Management Center (SDMC), which provides expertise in biostatistics, data management, and operational support for national clinical trials.

A clinical trial led by Neeraj Agarwal, MD, FASCO, found that a combination prostate cancer therapy could slow disease progression for patients with certain gene alterations, including BRCA.

In one San Antonio laboratory, scientists are studying how a single mutation allows cancer cells to outmaneuver therapy. Just a few buildings away, physicians are using that knowledge to shape clinical trials and treatment approaches for the patients most likely to benefit. The distance between those efforts is small, but what matters most is how […] The post Explore the engine accelerating new c…